STAT+: Biogen, fresh off major decisions on CEO and Aduhelm, faces next hurdles

Biogen, a stalwart of the global drug industry for the past four decades, is perilously poised for 2022.

Biogen, a stalwart of the global drug industry for the past four decades, is perilously poised for 2022.

The company’s Tuesday decisions to replace CEO Michel Vounatsos and cut nearly all spending marketing the Alzheimer’s disease treatment Aduhelm resolved some of the questions swirling around the embattled biotech.

Continue to STAT+ to read the full story…